Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Tissue Adhesive Versus Figure-of-Eight Suture for Femoral Venous Closure After Electrophysiology Procedures (GLUE-EP) (GLUE-EP)

3 listopada 2026 zaktualizowane przez: Otakar Jiravsky, Nemocnice AGEL Trinec-Podlesi a.s.

Topical Cyanoacrylate Tissue Adhesive Versus Figure-of-Eight Suture for Closure of Femoral Venous Access After Electrophysiology Procedures, Including Large-Bore Pulsed-Field Ablation: a Single-Centre Retrospective Cohort Study With Prospective Continuation (GLUE-EP)

In July 2026 the electrophysiology laboratory of a Czech tertiary cardiology centre introduced topical cyanoacrylate tissue adhesive (DERMABOND Mini or Histoacryl) as a routine alternative to the figure-of-eight suture for closing femoral venous puncture sites after electrophysiology procedures, including pulsed-field ablation performed through 13-17 F sheaths. After sheath removal, haemostasis is achieved by manual compression and the adhesive seals the skin over the puncture. The change was a clinical decision of the department, not a study intervention.

Published experience with this approach is limited, particularly for large-bore venous sheaths. GLUE-EP evaluates the access-site safety of the practice change using routinely recorded data only. Procedures closed with tissue adhesive are compared with a historical cohort closed with a figure-of-eight suture in 2024-2025 (propensity-score matched) and with a concurrent cohort closed with a suture during the same period. A prospective continuation collects the same routine data until 30 June 2027 from patients who give written informed consent.

The study assigns no treatment, adds no examination, questionnaire or study visit, and does not influence how the puncture site is closed. The primary outcome is any major or minor access-site vascular complication within 30 days of the procedure.

Przegląd badań

Szczegółowy opis

BACKGROUND

Closure of the femoral venous puncture site is the most frequent source of complications after electrophysiology (EP) procedures. The departmental standard has been a percutaneous figure-of-eight suture, removed 2 to 6 hours after the procedure. Topical cyanoacrylate tissue adhesive is an alternative that requires no removal: after sheath removal, haemostasis is achieved by manual compression and the adhesive then seals the skin over the puncture, which is the use for which the CE-marked products are intended. With the spread of pulsed-field ablation, venous sheath size has increased to 13-17 F, so the question of closure is most pressing for large-bore access. Published experience is limited: the only comparative report identified in PubMed concerns skin adhesive combined with a vascular closure device after atrial fibrillation ablation, not adhesive used instead of a suture.

PRACTICE CHANGE

Since 1 July 2026 the EP laboratory of Nemocnice AGEL Trinec-Podlesi a.s. (Czechia) has used topical cyanoacrylate tissue adhesive (2-octyl cyanoacrylate, DERMABOND Mini; or n-butyl-2-cyanoacrylate, Histoacryl) as a standard alternative to the figure-of-eight suture. This was a clinical decision of the department, not a research intervention. By 17 September 2026, 192 procedures had been closed with adhesive (177 catheter ablations and 15 diagnostic EP studies; 127 pulsed-field ablations through 13-17 F sheaths). Adhesive was used in 40%, 73% and 72% of procedures in July, August and September 2026, respectively.

DESIGN

Single-centre observational cohort study in two parts with identical population and outcome definitions. The study does not assign the closure method; it is chosen by the treating physician.

Part R (retrospective):

  • Group A: procedures closed with adhesive from 1 July 2026 to the date of the ethics committee opinion (data cut-off 30 September 2026 for the first analysis).
  • Group B: procedures closed with a figure-of-eight suture from 1 January 2024 to 31 December 2025 (historical comparator).
  • Group C: procedures of the same period as Group A closed with a figure-of-eight suture (concurrent comparator).

Part P (prospective continuation): procedures closed with adhesive from the day after the ethics committee opinion to 30 June 2027, in patients who gave written informed consent before the procedure. Consent is sought at admission from all patients scheduled for an elective EP procedure with femoral venous access, because the closure method is decided during the procedure; only patients whose puncture site is closed with adhesive enter the analysis. The same routine variables are collected from the same sources; apart from obtaining consent, there is no additional examination, measurement, questionnaire or patient contact.

ASCERTAINMENT OF THE CLOSURE METHOD

In 2026, adhesive use is recorded in the departmental procedure registry. For Groups B and C, the closure method is taken from the procedure report and discharge summary. Because the figure-of-eight suture was the departmental standard, a procedure is classified as suture-closed unless another method is documented; procedures with another documented method (compression alone, vascular closure device) are excluded. The proportion of procedures without an explicit record of the suture is reported, and a sensitivity analysis restricts Groups B and C to procedures with an explicit record.

ASCERTAINMENT OF OUTCOMES

Access-site complications are identified from discharge summaries and from all records in the hospital information system up to day 30 after the procedure (outpatient visits, emergency department visits, readmissions, telephone contacts), not from the complication field of the departmental registry. A procedure without any record after discharge is counted as having no recorded complication; the proportion of such procedures is reported by group, and these procedures are excluded in a sensitivity analysis.

STATISTICAL ANALYSIS

Groups A and B are matched 1:1 by propensity score (nearest neighbour without replacement, caliper 0.2 SD of the logit of the score, exact matching on sheath size 5-9 F versus 13-17 F). The score is estimated by logistic regression from age, sex, procedure type, ablation system, number and size of sheaths, antithrombotic therapy and ultrasound-guided puncture; balance is checked by standardised differences (target below 0.1). The primary comparison (Group A versus matched Group B) uses the McNemar test and conditional logistic regression (odds ratio with 95% confidence interval). The comparison with Group C uses covariate-adjusted logistic regression, with inverse probability weighting as a sensitivity analysis. Binary secondary outcomes are analysed by logistic regression and length of stay (nights) by negative binomial regression. Part P is analysed descriptively and compared with Group A, with complication and conversion rates shown by calendar quarter. The large-bore (13-17 F) subgroup is pre-specified and analysed descriptively.

There is no formal sample size calculation; all eligible procedures in the defined periods are included. The study is estimation-oriented and is not designed to demonstrate non-inferiority. With 192 adhesive procedures, 0, 2 and 4 observed events correspond to upper limits of the 95% Wilson confidence interval of 2.0%, 3.7% and 5.2%, respectively.

Not collected: time to haemostasis, time to ambulation, pain scores, patient satisfaction, closure cost and operator confidence. These are not recorded in routine documentation and will not be reported.

ETHICS AND DATA PROTECTION

The protocol was submitted to the Ethics Committee of Nemocnice AGEL Trinec-Podlesi a.s. in October 2026, with a request for waiver of informed consent for Groups A, B and C; written informed consent is obtained in Part P. The analytic dataset is pseudonymised; the key is held on a secure hospital server and is accessible only to the principal investigator. Only aggregate data are reported.

DISSEMINATION

Abstract at an international cardiology congress and publication in a peer-reviewed journal regardless of the direction of the results.

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

1400

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

      • Třinec, Czechy, 73961
        • Nemocnice AGEL Trinec-Podlesi a.s.
        • Kontakt:
        • Główny śledczy:
          • Otakar Jiravsky, MUDr., Ph.D., MBA
        • Pod-śledczy:
          • Bogdan Szmek, MUDr.
        • Pod-śledczy:
          • Jan Chovancik, MUDr., Ph.D., MBA
        • Pod-śledczy:
          • Radek Jancar, MUDr.
        • Pod-śledczy:
          • Ivan Ranic, MUDr., MBA
        • Pod-śledczy:
          • Jan Adamek, MUDr.
        • Pod-śledczy:
          • Martina Hrosova, MUDr.

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

Adults undergoing elective electrophysiology procedures (diagnostic EP studies and catheter ablations, including pulsed-field ablation) with femoral venous access at the electrophysiology laboratory of Nemocnice AGEL Trinec-Podlesi a.s., Czechia, identified consecutively from the departmental procedure registry within the defined periods.

Opis

Inclusion Criteria:

  • Age 18 years or older
  • Elective electrophysiology procedure (diagnostic study or catheter ablation) with at least one femoral venous sheath
  • Femoral venous puncture site closed with topical cyanoacrylate tissue adhesive (Groups A and P) or with a figure-of-eight suture (Groups B and C)
  • Group P only: written informed consent to the use of routine medical records

Exclusion Criteria:

  • Arterial access during the same procedure
  • Non-elective or emergency procedure
  • Groups B and C: documentation of a closure method other than a figure-of-eight suture (compression alone, vascular closure device)
  • Group P only: inability to understand the patient information or to give consent

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Modele obserwacyjne: COHORT
  • Perspektywy czasowe: OTHER

Kohorty i interwencje

Grupa / Kohorta
Interwencja / Leczenie
Group A: Tissue adhesive (retrospective)

Elective EP procedures with femoral venous puncture sites closed with topical cyanoacrylate tissue adhesive from 1 July 2026 to the date of the ethics committee opinion. Data from routine records; waiver of consent requested.

Routine clinical practice, not assigned by the study. After sheath removal and haemostasis by manual compression, the skin over the femoral venous puncture is sealed with CE-marked topical cyanoacrylate tissue adhesive: 2-octyl cyanoacrylate (DERMABOND Mini) or n-butyl-2-cyanoacrylate (Histoacryl).

Inne nazwy:
  • DERMABOND Mini
  • Histoacryl
Group B: Figure-of-eight suture (historical)

Elective EP procedures closed with a percutaneous figure-of-eight suture from 1 January 2024 to 31 December 2025; propensity-score matched 1:1 to Group A. Data from routine records; waiver of consent requested.

Routine clinical practice, not assigned by the study. Percutaneous figure-of-eight (purse-string) skin suture placed over the femoral venous puncture after sheath removal and released 2 to 6 hours later.

Group C: Figure-of-eight suture (concurrent)

Elective EP procedures of the same period as Group A (from 1 July 2026 to the date of the ethics committee opinion) in which adhesive was not used and the puncture site was closed with a figure-of-eight suture. Data from routine records; waiver of consent requested.

Routine clinical practice, not assigned by the study. Percutaneous figure-of-eight (purse-string) skin suture placed over the femoral venous puncture after sheath removal and released 2 to 6 hours later.

Group P: Tissue adhesive (prospective continuation)

Elective EP procedures closed with topical cyanoacrylate tissue adhesive from the day after the ethics committee opinion to 30 June 2027, in patients who gave written informed consent before the procedure. Same routine variables and sources as Group A.

Routine clinical practice, not assigned by the study. After sheath removal and haemostasis by manual compression, the skin over the femoral venous puncture is sealed with CE-marked topical cyanoacrylate tissue adhesive: 2-octyl cyanoacrylate (DERMABOND Mini) or n-butyl-2-cyanoacrylate (Histoacryl).

Inne nazwy:
  • DERMABOND Mini
  • Histoacryl

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Number of Participants With Access-Site Vascular Complications
Ramy czasowe: From the procedure through 30 days after the procedure

Any major or minor vascular complication at the femoral venous access site, using VARC-3 criteria adapted for venous access. Major: bleeding requiring transfusion or surgical or interventional revision; pseudoaneurysm or arteriovenous fistula requiring treatment; access-site infection requiring systemic antibiotics or revision; deep vein thrombosis. Minor: haematoma without transfusion or revision but with prolonged hospital stay or unplanned healthcare contact; pseudoaneurysm or fistula managed conservatively; local reaction requiring treatment. Ascertained from discharge summaries and all hospital records up to day 30. Primary comparison: Group A versus propensity-matched Group B; key secondary comparison: Group A versus Group C. Pre-specified subgroup: 13-17 F sheaths.

From the procedure through 30 days after the procedure

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Number of Participants Requiring Conversion From Tissue Adhesive to Figure-of-Eight Suture
Ramy czasowe: During the index procedure (day 0)

Conversion to a figure-of-eight suture because of inadequate haemostasis immediately after sheath removal, in procedures intended for adhesive closure (Groups A and P). Ascertained from the procedure report and discharge summary.

During the index procedure (day 0)
Number of Participants Discharged on the Day of the Procedure
Ramy czasowe: Day 0 (day of the procedure)

Discharge from hospital on the calendar day of the index procedure, as recorded in the departmental registry.

Day 0 (day of the procedure)
Length of Post-Procedural Hospital Stay
Ramy czasowe: From the procedure to hospital discharge, assessed up to 30 days

Number of nights spent in hospital after the index procedure, taken from the discharge summary.

From the procedure to hospital discharge, assessed up to 30 days
Number of Participants With Unplanned Healthcare Contact Related to the Access Site
Ramy czasowe: From discharge through 30 days after the procedure

Any unplanned outpatient visit, emergency department visit, readmission or telephone contact related to the femoral access site, as recorded in the hospital information system.

From discharge through 30 days after the procedure

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Otakar Jiravsky, MUDr., Ph.D., MBA, Nemocnice AGEL Trinec-Podlesi a.s.

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 grudnia 2026

Zakończenie podstawowe (Szacowany)

1 lipca 2027

Ukończenie studiów (Szacowany)

1 września 2027

Daty rejestracji na studia

Pierwszy przesłany

3 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

3 listopada 2026

Pierwszy wysłany (Rzeczywisty)

9 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

9 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

3 listopada 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Opis planu IPD

Only aggregate results will be published. Individual participant data will not be shared: the retrospective part relies on a waiver of consent, and participants in the prospective part consent to the use of their pseudonymised data by the study team only.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

produkt wyprodukowany i wyeksportowany z USA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj